Conversely, induction of DRP1 through inhibiting anti-apoptotic proteins BCL-2 or activating Sirt3 (histone deacetylase) by ABT737 (an inhibitor of antiapoptotic BCL-2/BCL-X) promotes fission, leading to apoptosis and mitophagy in ovarian cancer cells resistant to cisplatin [453,455,471]. This evidence concerns the gene BCL2 and ovarian carcinoma.